SRDX
Price
$26.75
Change
-$0.46 (-1.69%)
Updated
May 9, 04:58 PM (EDT)
Capitalization
397.04M
82 days until earnings call
TFX
Price
$125.15
Change
-$1.03 (-0.82%)
Updated
May 9, 04:59 PM (EDT)
Capitalization
10.49B
76 days until earnings call
Ad is loading...

SRDX vs TFX

Header iconSRDX vs TFX Comparison
Open Charts SRDX vs TFXBanner chart's image
Surmodics
Price$26.75
Change-$0.46 (-1.69%)
Volume$458
Capitalization397.04M
Teleflex
Price$125.15
Change-$1.03 (-0.82%)
Volume$3.04K
Capitalization10.49B
SRDX vs TFX Comparison Chart
Loading...
SRDX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
TFX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
SRDX vs. TFX commentary
May 09, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is SRDX is a Hold and TFX is a Hold.

Ad is loading...
COMPARISON
Comparison
May 09, 2025
Stock price -- (SRDX: $27.21 vs. TFX: $126.18)
Brand notoriety: SRDX and TFX are both not notable
Both companies represent the Medical Specialties industry
Current volume relative to the 65-day Moving Average: SRDX: 39% vs. TFX: 53%
Market capitalization -- SRDX: $397.04M vs. TFX: $10.49B
SRDX [@Medical Specialties] is valued at $397.04M. TFX’s [@Medical Specialties] market capitalization is $10.49B. The market cap for tickers in the [@Medical Specialties] industry ranges from $3.82T to $0. The average market capitalization across the [@Medical Specialties] industry is $8.43B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

SRDX’s FA Score shows that 0 FA rating(s) are green whileTFX’s FA Score has 2 green FA rating(s).

  • SRDX’s FA Score: 0 green, 5 red.
  • TFX’s FA Score: 2 green, 3 red.
According to our system of comparison, TFX is a better buy in the long-term than SRDX.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

SRDX’s TA Score shows that 3 TA indicator(s) are bullish while TFX’s TA Score has 4 bullish TA indicator(s).

  • SRDX’s TA Score: 3 bullish, 5 bearish.
  • TFX’s TA Score: 4 bullish, 4 bearish.
According to our system of comparison, TFX is a better buy in the short-term than SRDX.

Price Growth

SRDX (@Medical Specialties) experienced а -2.33% price change this week, while TFX (@Medical Specialties) price change was +0.25% for the same time period.

The average weekly price growth across all stocks in the @Medical Specialties industry was +2.36%. For the same industry, the average monthly price growth was +7.93%, and the average quarterly price growth was -3.96%.

Reported Earning Dates

SRDX is expected to report earnings on Jul 30, 2025.

TFX is expected to report earnings on Jul 24, 2025.

Industries' Descriptions

@Medical Specialties (+2.36% weekly)

Medical specialties are companies that make equipment used by the health care industry. Equipment manufactured and distributed by these companies include dialysis machines, blood analysis equipment, surgical equipment, dental instruments, and diagnostic tools, among other items. Large companies typically aim to produce and distribute high-quality products across a broad market spectrum. Smaller firms are more likely to specialize in a particular market segment. Due to the industry’s close association with medical treatments, they typically have low sensitivity to macroeconomic fluctuations. Within this industry, Abbott Laboratories, Medtronic Plc and Thermo Fisher Scientific Inc. are some of the companies with multi-billion market capitalizations in the U.S. stock markets.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
TFX($10.5B) has a higher market cap than SRDX($397M). SRDX has higher P/E ratio than TFX: SRDX (71.51) vs TFX (29.48). TFX YTD gains are higher at: -28.927 vs. SRDX (-31.288). TFX has higher annual earnings (EBITDA): 761M vs. SRDX (22.1M). TFX has more cash in the bank: 223M vs. SRDX (35.2M). SRDX has less debt than TFX: SRDX (33.9M) vs TFX (1.93B). TFX has higher revenues than SRDX: TFX (2.97B) vs SRDX (138M).
SRDXTFXSRDX / TFX
Capitalization397M10.5B4%
EBITDA22.1M761M3%
Gain YTD-31.288-28.927108%
P/E Ratio71.5129.48243%
Revenue138M2.97B5%
Total Cash35.2M223M16%
Total Debt33.9M1.93B2%
FUNDAMENTALS RATINGS
SRDX vs TFX: Fundamental Ratings
SRDX
TFX
OUTLOOK RATING
1..100
6157
VALUATION
overvalued / fair valued / undervalued
1..100
92
Overvalued
13
Undervalued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
9188
PRICE GROWTH RATING
1..100
8164
P/E GROWTH RATING
1..100
9431
SEASONALITY SCORE
1..100
85n/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

TFX's Valuation (13) in the Medical Specialties industry is significantly better than the same rating for SRDX (92). This means that TFX’s stock grew significantly faster than SRDX’s over the last 12 months.

TFX's Profit vs Risk Rating (100) in the Medical Specialties industry is in the same range as SRDX (100). This means that TFX’s stock grew similarly to SRDX’s over the last 12 months.

TFX's SMR Rating (88) in the Medical Specialties industry is in the same range as SRDX (91). This means that TFX’s stock grew similarly to SRDX’s over the last 12 months.

TFX's Price Growth Rating (64) in the Medical Specialties industry is in the same range as SRDX (81). This means that TFX’s stock grew similarly to SRDX’s over the last 12 months.

TFX's P/E Growth Rating (31) in the Medical Specialties industry is somewhat better than the same rating for SRDX (94). This means that TFX’s stock grew somewhat faster than SRDX’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
SRDXTFX
RSI
ODDS (%)
Bullish Trend 2 days ago
72%
Bullish Trend 2 days ago
72%
Stochastic
ODDS (%)
Bullish Trend 2 days ago
63%
Bullish Trend 2 days ago
58%
Momentum
ODDS (%)
Bearish Trend 2 days ago
66%
Bearish Trend 2 days ago
71%
MACD
ODDS (%)
Bearish Trend 2 days ago
71%
Bearish Trend 2 days ago
72%
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
70%
Bullish Trend 2 days ago
56%
TrendMonth
ODDS (%)
Bearish Trend 2 days ago
70%
Bearish Trend 2 days ago
71%
Advances
ODDS (%)
Bullish Trend 12 days ago
68%
Bullish Trend 2 days ago
56%
Declines
ODDS (%)
Bearish Trend 5 days ago
68%
Bearish Trend 4 days ago
72%
BollingerBands
ODDS (%)
Bearish Trend 2 days ago
74%
Bullish Trend 3 days ago
53%
Aroon
ODDS (%)
N/A
Bearish Trend 2 days ago
68%
View a ticker or compare two or three
Ad is loading...
SRDX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
TFX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
RESGX14.960.08
+0.54%
Glenmede Environmental Accountability
JRSCX10.850.05
+0.46%
JH Adaptive Risk Mgd U.S. Eq C
GSTTX12.45N/A
N/A
Goldman Sachs Strategic Growth Inv
MSTQX12.32N/A
N/A
Morningstar US Equity
MKVEX14.88N/A
N/A
MFS International Large Cap Value R2

SRDX and

Correlation & Price change

A.I.dvisor tells us that SRDX and RMD have been poorly correlated (+32% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that SRDX and RMD's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To SRDX
1D Price
Change %
SRDX100%
+0.20%
RMD - SRDX
32%
Poorly correlated
-0.44%
BDX - SRDX
31%
Poorly correlated
+0.48%
UFPT - SRDX
28%
Poorly correlated
+6.48%
TFX - SRDX
28%
Poorly correlated
+3.36%
MBOT - SRDX
26%
Poorly correlated
+1.99%
More

TFX and

Correlation & Price change

A.I.dvisor indicates that over the last year, TFX has been loosely correlated with TNDM. These tickers have moved in lockstep 51% of the time. This A.I.-generated data suggests there is some statistical probability that if TFX jumps, then TNDM could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To TFX
1D Price
Change %
TFX100%
+3.36%
TNDM - TFX
51%
Loosely correlated
+2.16%
RVTY - TFX
42%
Loosely correlated
+1.43%
A - TFX
42%
Loosely correlated
+1.10%
WAT - TFX
41%
Loosely correlated
+1.57%
IQV - TFX
41%
Loosely correlated
-0.01%
More